140 related articles for article (PubMed ID: 37932739)
1. Randomized clinical trial of low dose suramin intravenous infusions for treatment of autism spectrum disorder.
Hough D; Mao AR; Aman M; Lozano R; Smith-Hicks C; Martinez-Cerdeno V; Derby M; Rome Z; Malan N; Findling RL
Ann Gen Psychiatry; 2023 Nov; 22(1):45. PubMed ID: 37932739
[TBL] [Abstract][Full Text] [Related]
2. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.
Nasser A; Hull JT; Chaturvedi SA; Liranso T; Odebo O; Kosheleff AR; Fry N; Cutler AJ; Rubin J; Schwabe S; Childress A
CNS Drugs; 2022 Aug; 36(8):897-915. PubMed ID: 35896943
[TBL] [Abstract][Full Text] [Related]
3. Low-dose suramin in autism spectrum disorder: a small, phase I/II, randomized clinical trial.
Naviaux RK; Curtis B; Li K; Naviaux JC; Bright AT; Reiner GE; Westerfield M; Goh S; Alaynick WA; Wang L; Capparelli EV; Adams C; Sun J; Jain S; He F; Arellano DA; Mash LE; Chukoskie L; Lincoln A; Townsend J
Ann Clin Transl Neurol; 2017 Jul; 4(7):491-505. PubMed ID: 28695149
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
5. Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder.
Zimmerman AW; Singh K; Connors SL; Liu H; Panjwani AA; Lee LC; Diggins E; Foley A; Melnyk S; Singh IN; James SJ; Frye RE; Fahey JW
Mol Autism; 2021 May; 12(1):38. PubMed ID: 34034808
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
8. A pilot study of high-dose intravenous immunoglobulin 5% for autism: Impact on autism spectrum and markers of neuroinflammation.
Melamed IR; Heffron M; Testori A; Lipe K
Autism Res; 2018 Mar; 11(3):421-433. PubMed ID: 29427532
[TBL] [Abstract][Full Text] [Related]
9. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
10. Balovaptan vs Placebo for Social Communication in Childhood Autism Spectrum Disorder: A Randomized Clinical Trial.
Hollander E; Jacob S; Jou R; McNamara N; Sikich L; Tobe R; Smith J; Sanders K; Squassante L; Murtagh L; Gleissl T; Wandel C; Veenstra-VanderWeele J
JAMA Psychiatry; 2022 Aug; 79(8):760-769. PubMed ID: 35793101
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of balovaptan for socialisation and communication difficulties in autistic adults in North America and Europe: a phase 3, randomised, placebo-controlled trial.
Jacob S; Veenstra-VanderWeele J; Murphy D; McCracken J; Smith J; Sanders K; Meyenberg C; Wiese T; Deol-Bhullar G; Wandel C; Ashford E; Anagnostou E
Lancet Psychiatry; 2022 Mar; 9(3):199-210. PubMed ID: 35151410
[TBL] [Abstract][Full Text] [Related]
13. Improved symptoms following bumetanide treatment in children aged 3-6 years with autism spectrum disorder: a randomized, double-blind, placebo-controlled trial.
Dai Y; Zhang L; Yu J; Zhou X; He H; Ji Y; Wang K; Du X; Liu X; Tang Y; Deng S; Langley C; Li WG; Zhang J; Feng J; Sahakian BJ; Luo Q; Li F
Sci Bull (Beijing); 2021 Aug; 66(15):1591-1598. PubMed ID: 36654288
[TBL] [Abstract][Full Text] [Related]
14. Cannabinoid treatment for autism: a proof-of-concept randomized trial.
Aran A; Harel M; Cassuto H; Polyansky L; Schnapp A; Wattad N; Shmueli D; Golan D; Castellanos FX
Mol Autism; 2021 Feb; 12(1):6. PubMed ID: 33536055
[TBL] [Abstract][Full Text] [Related]
15. A randomized double-blind, placebo-controlled pilot trial of mirtazapine for anxiety in children and adolescents with autism spectrum disorder.
McDougle CJ; Thom RP; Ravichandran CT; Palumbo ML; Politte LC; Mullett JE; Keary CJ; Erickson CA; Stigler KA; Mathieu-Frasier L; Posey DJ
Neuropsychopharmacology; 2022 May; 47(6):1263-1270. PubMed ID: 35241779
[TBL] [Abstract][Full Text] [Related]
16. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic Replacement Therapy for Maladaptive Behaviors in Preschool Children With Autism Spectrum Disorder.
Pearson DA; Hendren RL; Heil MF; McIntyre WR; Raines SR
JAMA Netw Open; 2023 Nov; 6(11):e2344136. PubMed ID: 38032645
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of intravenous vitamin C in management of moderate and severe COVID-19: A double blind randomized placebo controlled trial.
Kumar V; Bhushan D; Supriya S; Ganapule AA; Lohani P; Shyama ; Pandey S; Majhi PK; Anand U; Kumar R; Bhadani UK
J Family Med Prim Care; 2022 Aug; 11(8):4758-4765. PubMed ID: 36352995
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled, Forced-Dose Clinical Study.
Weisler RH; Greenbaum M; Arnold V; Yu M; Yan B; Jaffee M; Robertson B
CNS Drugs; 2017 Aug; 31(8):685-697. PubMed ID: 28712074
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of methylphenidate and behavioural parent training for children aged 3-5 years with attention-deficit hyperactivity disorder: a randomised, double-blind, placebo-controlled, and sham behavioural parent training-controlled trial.
Sugaya LS; Salum GA; de Sousa Gurgel W; de Morais EM; Del Prette G; Pilatti CD; Dalmaso BB; Leibenluft E; Rohde LA; Polanczyk GV
Lancet Child Adolesc Health; 2022 Dec; 6(12):845-856. PubMed ID: 36306807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
